|
 |
Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3: 402-408.
Kharbanda S, Pandey P, Morris PL, Whang Y, Xu Y, Sawant S, Zhu LJ, Kumar N, Yuan ZM, Weichselbaum R, Sawyers CL, Pandita TK, Kufe D. Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene 1998; 16: 1773-1777.
Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001; 98: 10320-10325.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP. Mutations in the mitotic Check point gene, MAD1L1, in human cancers. Oncogene 2001; 20: 3301-3305.
Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 2001; 15: 757-763.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwiser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brian SG, Russell N, Fischer T, Ottmann O, Cony- Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002; 346: 645-652.
Ottman OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ. Imatinib induces hematologic and cytogenic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002: 99: 3530-3539.
Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-942.
Jamison CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med 2005; 46: 114-120.
Kim JH, Kim B, Cai L, Choi HJ, Ohgi KA, Tran C, Chen C, Chung CH, Huber O, Rose DW, Sawyers CL, Rosenfeld MG, Baek SH. Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta catenin complexes. Nature 2005; 434: 921-926.
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs VL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024.
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005; 102: 11011-11016.
Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005; 44: 351-364.
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006; 66: 1007-1014.
Radich JP, Dai H. Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006: 103: 2794-2799.
Chandra J, Tracy J, Loegering D, Flatten K, Verstovesk S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 2006; 107: 2501-2506.
Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise L, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen T, Huang F, Decillis A, Sawyers CL. Activity of the ABL kinase inhibitor desatinib in imatinib-resistant Philadelphia chromosome positive leukemias. New Engl J Med 2006; 324:2531-2541.
Wang MY, Lu KV, Zhu S, Dia EQ, Vivanko I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006; 66: 7864-7869.
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, Debiasi RM, Yoshimoto K, King JC, Ngiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Kahn H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Myerson M, Mellinghoff IK. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2005; 3: e485 [Epub ahead of print].
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A 2006; 103: 19466-19471.
Mehrian SR, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV, Sawyers CL. IGFBP2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; In Press.
Witte ON, Kelliher M, Muller A, Pendergast AM, Gishizky M, McLaughlin J, Sawyers CL, Maru Y, Shah N, Denny C, Rosenberg N. Role of the BCR-ABL oncogene in the pathogenesis of Philadelphia chromosome positive leukemias. In: Origins of Human Cancer: A Comprehensive Review. Brugge J, Curran T, Harlow E, McCormick F (eds). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1991, pp. 521-526.
Afar DEH, Goga A, Cohen L, Sawyers CL, McLaughlin J, Mohr RN, Witte ON. Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. In: Molecular Genetics of Cancer - Symposium 50. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1994, pp. 589-594.
Sawyers CL, Witte ON. The c-ABL protein tyrosine kinase. In: Protein Kinase Factsbook. Hardie DG, Hanks S, (eds). London, UK: Academic Press; 1994, pp. 100-102.
Sawyers CL, Goga A, Afar D, McLaughlin J, Witte ON. Positive and negative growth effects of Abl genes. In: Normal and Malignant Hematopoiesis. Mihich E, Metcalf D, (eds). New York, NY: Plenum Press; 1995, pp. 119-127.
Sawyers CL. Molecular genetics of acute leukemias. In: Wintrobe's Clinical Hematology. 10th Edition. Philadelphia, PA: William & Wilkins; 1999.
Mellinghoff I, Sawyers CL. Kinase inhibitor therapy in cancer. In: Principles & Practice of Oncology Updates. DeVita V, Hellman S, Rosenberg SA, (eds). Philadelphia, PA: Lippincott, Williams & Wilkins; 2000; 14(12): 1-11.
Sellers W, Sawyers CL. Somatic genetics of prostate cancer, oncogenes and tumor suppressors. In: Prostate Cancer: Principles and Practice. Kantoff PW, Carroll PR, D'Amico AV, (eds). Philadelphia, PA: Lippencott, William & Wilkins; 2002
Reiter RE, Sawyers CL. Xenograft models and the molecular biology of human prostate cancer. In: Prostate cancer: biology, genetics, and the new therapeutics. Isaacs WB, Chung L, Simons JW, (eds). Totawa, NJ: Humana Press; 2001, pp. 163-174.
Shah NP, Sawyers CL. Chronic myeloid leukemia. In: Chronic leukemias and lymphoms: biology, pathophysiology, and clinical management. Schiller GJ, (ed). Totawa, NJ: Humana Press; 2003; pp. 93-114.
Ellwood -Yen, Sawyers CL. Prostate Cancer. In: Mouse models of human cancer. Holland EC, (ed). Hoboken, NJ: Wiley-Liss; 2004; pp. 133-150.
Sawyers CL, Shah NP. Chronic Myeloid Leukemia. Chapter 69 in: Hematology: basic principles and practice. Hoffman R, Benz EJ, Shattil SH, Furie B, Cohen HJ, Silberstein LE, McGlave P, (eds). Philadelphia, PA: Churchill Livingstone; 2005.
Sawyers CL. Chromosomal translocators in human leukemias: molecular mechanisms of oncogenic fusion proteins. Advances in Leukemia and Lymphoma 1993; 4: 1-11.
Greenberg PL, de Wald G, Sawyers CL. Myeloproliferative disorders and myelodysplastic syndromes: recent therapeutic, cytogenetic, and molecular advances. Hematology Am Soc Hematol Edu Program 1994: 21-33.
Greenberg PL, O'Brien S, Goldman J, Sawyers CL. Myelodysplastic syndromes and myeloproliferative disorders: clinical, therapeutic, and molecular advances. Hematology Am Soc Hematol Edu Program 1995: 10-21.
Sawyers CL. Tele-lecture clinics: hematopoietic therapy, "The molecular biology of chronic myelogenous leukemia," 1995; 4(2): 6-7.
Seltzer V, Batson JL, Drukker BH, Gillespie BW, Gossfield LM, Grisby PW, Harvey HA, Hendricks CB, Hummel S, Makuch RW, Monaco GP, Parham GP, Sawyers CL, West RJ. NIH Consensus Conference. Ovarian cancer: screening, treatment and follow-up. JAMA 1995: 273(6): 491-497.
Carella AM, Frassoni F, Melo J, Sawyers CL, Eaves A, Apperley J, Tura S, Hehlmann R, Reiffers J, Lerma E, Goldman J. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82(4): 478-495.
Sawyers CL. Chronic myelogenous leukemia: impacts of molecular biology on therapy - a new paradigm for cancer treatment. Am Soc Clin Oncol 2000; Education Session.
|
|
|
|
